New drug offers hope for rare swelling disorder patients
NCT ID NCT07290855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called icatibant (Icanticure) in 5 adults with a rare condition that causes sudden, painful swelling attacks. The goal was to see how quickly the drug relieved symptoms and if it was safe. Participants received the injection for free during an acute attack, and researchers tracked their pain and swelling relief over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRADYKININ-MEDIATED ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taichung Veterans General Hospital
Taichung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
- Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
- Takhzyro under the microscope: Real-World safety check for rare swelling disease
- New hope for HAE patients: experimental drug aims to slash attack rate
- New RNA drug shows promise in preventing HAE attacks in ongoing study
- New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder